Phase I Trial of the Effects of LCI699 (Osilodrostat) on Cytochrome P450 Enzymes in Healthy Volunteers.

Trial Profile

Phase I Trial of the Effects of LCI699 (Osilodrostat) on Cytochrome P450 Enzymes in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Osilodrostat (Primary)
  • Indications Cushing syndrome
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 02 Feb 2017 Results published in the Clinical Drug Investigation
    • 11 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top